Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.
文献类型：期刊论文
| 作者 | Shen, Lin; Gong, Jifang; Zhang, Jian; Ji, Dongmei; Zhong, Haijun; Yuan, Ying; Yang, Lei ; Zhang, Qingyuan; Li, Yufeng; Wang, Mengde
|
| 刊名 | JOURNAL OF CLINICAL ONCOLOGY
 |
| 出版日期 | 2021-05-20 |
| 卷号 | 39 |
| ISSN号 | 0732-183X |
| DOI | 10.1200/JCO.2021.39.15_suppl.e14547 |
| 资助项目 | Mabspace Biosciences (Suzhou) Co., Limited, Suzhou, China |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000708120301043 |
| 出版者 | LIPPINCOTT WILLIAMS & WILKINS |
| 资助机构 | Mabspace Biosciences (Suzhou) Co., Limited, Suzhou, China |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/126478]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Harbin Med Univ Canc Hosp, Harbin, Peoples R China 2.Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China 3.Peking Univ, Sch Oncol, Beijing, Peoples R China 4.Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China 5.Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China 6.Univ Chinese Acad Sci, Canc Hosp, Chinese Acad Sci,Dept Med Oncol, Zhejiang Canc Hosp,Inst Canc & Basic Med, Hangzhou, Peoples R China 7.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China 8.Mabspace Biosci Suzhou Co Ltd, Suzhou, NJ, Peoples R China 9.Fudan Univ, Dept Med Oncol, Canc Hosp, Shanghai, Peoples R China 10.Mabspace Biosci Co Ltd, Suzhou, NJ, Peoples R China |
| 推荐引用方式 GB/T 7714 | Shen, Lin,Gong, Jifang,Zhang, Jian,et al. Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39. |
| APA | Shen, Lin.,Gong, Jifang.,Zhang, Jian.,Ji, Dongmei.,Zhong, Haijun.,...&Hu, Xichun.(2021).Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study..JOURNAL OF CLINICAL ONCOLOGY,39. |
| MLA | Shen, Lin,et al."Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.".JOURNAL OF CLINICAL ONCOLOGY 39(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。